Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Antonio Decarli

Gastroenterology New Smyrna Beach, FL Medical Doctor

NPI 1376644328 CMS profile 244410

1722 State Road 44, New Smyrna Beach, FL 32168

Open in the dashboard

General payments

$6,426

269 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$189,177 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Antonio Decarli of New Smyrna Beach, FL is reported in the CMS Open Payments database as having received $6,426 across 269 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $189,177 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 72nd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,479 75
2024 General $1,543 43
2023 General $220 12
2022 General $870 59
2021 General $621 37
2020 General $435 27
2019 General $258 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Antonio Decarli
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Antonio Decarli were reported at $2,479. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Antonio Decarli Gastroenterology median Middle half National median
2019 $258 $417 $126–$1,100 $163
2020 $435 $224 $74–$624 $114
2021 $621 $352 $106–$1,054 $132
2022 $870 $448 $129–$1,270 $149
2023 $220 $533 $150–$1,390 $160
2024 $1,543 $605 $160–$1,606 $164
2025 $2,479 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,371 117 payments
  2. Janssen Biotech, Inc. $413 24 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $339 17 payments
  4. Celltrion USA Inc. $279 15 payments
  5. Ipsen Biopharmaceuticals, Inc $259 5 payments
  6. Braintree Laboratories, Inc. $220 10 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $217 12 payments
  8. Ferring Pharmaceuticals Inc. $174 11 payments
  9. Merck Sharp & Dohme Corporation $116 6 payments
  10. Evoke Pharma, Inc. $113 6 payments
  11. Other $924 46 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,890 258 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,499 9 payments
  3. Education $37 2 payments
Products named General payments · program years 2019–2025
  1. LINZESS $650 47 payments
  2. CREON $585 40 payments
  3. RINVOQ $578 22 payments
  4. SKYRIZI Immunology $357 16 payments
  5. IQIRVO $259 5 payments
  6. ENTYVIO $239 12 payments
  7. VEGZELMA $219 12 payments
  8. TREMFYA $205 11 payments
  9. SKYRIZI Immunology $162 7 payments
  10. XIFAXAN $161 9 payments
  11. Other $2,538 144 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

946

Median for Gastroenterology: 569

Drug cost

$212,488

Median for Gastroenterology: $104,976

Branded share of claims

39.4%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 26 $137,293
Linzess Linaclotide Brand 46 $41,586
Suflave Peg 3350/Sod Sulf,chlr/Pot/Mag Brand 80 $9,787
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 36 $6,041
Mesalamine Generic 23 $4,807
Pantoprazole Sodium Generic 225 $3,039
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 115 $2,087
Famotidine Generic 105 $1,665
Omeprazole Generic 74 $1,176
Dicyclomine Hcl Generic 32 $899

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$109,002

Medicare's payments for the services billed

Medicare patients

520

Average age 74

Services billed

908

280 women, 240 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Ischemic heart disease 37%
Chronic kidney disease 31%
Diabetes 26%
COPD 26%
Depression 25%
Atrial fibrillation 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $233
$233 — —
SKYRIZI
  • AbbVie, Inc. $217
$217 — —
SUFLAVE
  • Braintree Laboratories, Inc. $85
$85 80 —
BOTOX
  • AbbVie, Inc. $75
$75 — —
LINZESS
  • AbbVie, Inc. $45
  • Ironwood Pharmaceuticals, Inc $15
$60 46 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

269 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record